Opko Health Inc (OPK)

[game7alcs]

I have watched AVXL but won’t jump in until I get rid of this one. Good Luck with it.. I hope it does well.

[tredenwater2]

Many companies were a giant waste of time these last few years. Largely due in part to the giant sucking sound of Amazon, aaple, tesla and the like asphyxiating the rest of the market. And the big three BP’s taking in multiple billions of dollars….I think they literally have my grandkids future savings account numbers. It has all been an over exuberant market built on lies, lies, and more damn lies! When does the musical chairs end?

I still like Mux when gold and silver explode and Im sticking with Avxl for my wildcat baby bio. Im hoping it becomes “insulated” from the market with in 6 months.

Good luck!

[game7alcs]

I have reached the point of just wanting an exit. A waste of time and money. Strongest market of my lifetime and I sat on way too much cash here. Terrible leadership. It’s nothing but a cash sucking party for them. They could sell this for $20share and I would consider it an epic failure.

[tredenwater2]

I think I would be more worried if this didnt happen considering the history here.

[game7alcs]

Of course

https://stocks.apple.com/AcgtkbcWdQuqNpGk3KqdvSw

[hang on]

Word has it Frosty will retire his personal shares when he retires or passes on from this world. (Not his trusted shares) So his personally boughten share should be looked at as a company buyback plan to be retired at a later date!! Just dreamin, but how sweet would it be if Frosty gave back to his shareholders in this way,

[game7alcs]

I don’t completely disagree. The saying “follow the money” holds true for every second of everything in our lives. I find it hard to believe there are many investment relationships over the years that are worse than the one between OPKO management and it’s shareholders. If it weren’t for Dr Cohen and unfortunately the pandemic we we would have been in the $1s at best. We need a real management team that wants to succeed not one that wants to suck the money and the life out of the company. Keep Dr Cohen and get rid of the rest.

[XenaLives]

I've been following SINT for several years. They are working on Silicon Nitride which should be superior to the titanium used in prosthetics whick is KNOWN to be toxic. They have a connection with the major manufacturer but it just goes nowhere..

Makes you seriously consider that the medical establishment just wants to keep us sick so they can make money.

[game7alcs]

I used to believe there was a wink and a nod but not so sure anymore. I think top mgt is milking the company and the shareholders for everything they can. Rayaldee was approved and they have done NOTHING with it. In the last cc they still used the pandemic as the excuse. Low vitamin D levels have been shown to cause more severe problems from Covid. We have Rayaldee and they sat on it. Even if it can only be used for CKD patients, they didn’t push for that and they are vulnerable. 4K score is just there. They hyped it and nothing. BLR was the most visible Covid tester and we have very little $ to show for it. To this point it is a manipulated EPIC failure.

[XenaLives]

Thanks for the insight, LOL!!!

Is it possible that there is a wink and a nod deal with Big Pharma for a buyout so they don't have to take the R&D risk?

Also Big Pharma will want to poison people with toxic meds as long as possible because it is avery profitable business model. If folks wake up they can change the game plan.

[game7alcs]

The CEO buys a lot and owns 30+% here. There are a lot of long term holders here expecting a billionaire like Dr Frost to sell at some point. If you enjoy banging your head against the wall you can invest here. Nobody knows where this is headed. It’s a crap shoot.

[game7alcs]

The deal hasn’t closed yet.

[game7alcs]

You better hurry because within minutes after I sell, Dr Frost will announce a sale at a huge premium lol

[XenaLives]

That's odd since it's still on the site...

[nbm16yankees]

Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

Program Supports Access to A Pivotal Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (DCA/PDCD trial; NCT02616484)

News provided by
Saol Therapeutics

Mar 01, 2022, 06:00 ET
Share this article

ROSWELL, Ga., March 1, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) who may be eligible to participate in a Phase 3 clinical trial. PDCD affects less than 300 children in the United States annually and lacks any FDA-approved treatment.

This pivotal phase 3 trial administers the investigational drug dichloroacetate (DCA) to young children who have a deficiency of the pyruvate dehydrogenase complex (PDC). PDC deficiency is the most common cause of congenital lactic acidosis and is frequently a fatal metabolic disease of childhood. DCA has Orphan Product designation from the FDA for congenital lactic acidosis (CLA), including patients with PDCD.

GeneDx, in collaboration with Saol, will help make clinicians who treat PDCD aware of this pivotal trial.

GeneDx's advanced genetic testing provides diagnostic information on disease-causing genetic changes thanks to expert gene variant interpretation built on the combination of an unparalleled dataset and deep clinical knowledge. Through the program, GeneDx, in collaboration with Saol, will help make clinicians who treat PDCD aware of this pivotal trial in an effort to possibly accelerate patient recruitment among this highly targeted patient population.

Dr. Peter Stacpoole, Principal Investigator of the DCA/PDCD trial and Prof. of Medicine at the University of Florida, notes, "There are currently no FDA-approved treatments for patients with PDCD. Despite this, finding and recruiting children appropriate for participation in clinical trials is not easy. With the help of GeneDx, we hope to complete trial recruitment this year."

Dave Penake, CEO of Saol Therapeutics, is excited about the collaboration with GeneDx. "Individualized genetic screening offers physicians and families the insights needed to avoid years of misdiagnosis. With their help, we are better able to identify mitochondrial diseases early. Without this technology, recruitment for a disease like PDCD could take many years to complete."

About Saol Therapeutics
Saol Therapeutics (pronounced "Sail") is a privately held, biopharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. Saol is focused on clinical development activity in rare diseases, with a focus on mitochondrial disorders, as well as central nervous system disorders such as spasticity and pain management. Saol is one of the collaborators on a Phase 3 trial studying the first potential treatment for pyruvate dehydrogenase complex deficiency (PDCD). More information on the clinical trial can be found at Phase 3 PDCD Trial. More information about Saol can be found at https://saolrx.com/.

About GeneDx
GeneDx, Inc. is a global leader in genomics, providing testing to patients and their families from more than 55 countries. Originally founded by scientists from the National Institutes of Health, GeneDx offers a world-renowned clinical genomics program with particular expertise in rare and ultra-rare genetic disorders. In addition to its market-leading exome sequencing service, GeneDx offers a suite of additional genetic testing services, including diagnostic testing for hereditary cancers, cardiac, mitochondrial, neurological disorders, prenatal diagnostics, and targeted variant testing. GeneDx is a subsidiary of BioReference Laboratories, Inc., a wholly owned subsidiary of OPKO Health, Inc. To learn more, please visit https://www.genedx.com/.

SOURCE Saol Therapeutics

[nbm16yankees]

Selling Genedx to Sema4 (SMFR)
OPK gets $150 million and 80 million shares of SMFR

[nbm16yankees]

I dont think it is diagnosing anything.
I believe they wrote claros off a few qtrs back.

[nbm16yankees]

No problem.
However, OPK is in the process of selling this to Sema4.

[XenaLives]

Hmm... This is what I was looking for, so how does this sale affect the value of the company?

STAMFORD, Conn. and MIAMI, Jan. 18, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a multinational biopharmaceutical and diagnostics company, today announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc. (“GeneDx”), a leader in genomic testing and analysis, from OPKO. The acquisition strengthens Sema4’s leadership, growth, and scale for its market-leading health intelligence and genomic screening offerings. Together, Sema4 and GeneDx will be one of the largest and most advanced providers of genomic clinical testing in the U.S., with a projected $350 million in pro forma 2022 revenue.

Following completion of the acquisition, Sema4 will be optimally positioned to partner with health systems and biopharma companies to further transform the standard of care throughout the patient health journey. GeneDx’s leadership in rare disease diagnostic and exome sequencing services brings more than 300,000 clinical exomes and over 2.1 million expertly annotated phenotypes to strengthen Sema4’s 12 million de-identified clinical records for Centrellis®, its proprietary health intelligence platform, and Traversa™, its comprehensive genomic analysis platform for optimizing health screenings. Sema4 plans to leverage this combined health information database to transform patient care and therapeutic development and enable precision medicine for all.

more..

https://www.bioreference.com/sema4-to-acquire-genedx/

[XenaLives]

Does anyone know if this device will be diagnosing mitochondrial level dysfunction? I see this as the future of medicine...

Claros® 1
The Claros® 1 device is a point-of-care, bench top diagnostic instrument system designed to provide rapid, quantitative blood test results in 15 minutes, right in the physician's office, using a fingerstick of whole blood. The Sangia Total PSA Claros® 1 test, which provides measurements comparable to large instruments used in central reference laboratories, received FDA approval in January 2019. Additional test menu options for this platform are planned for future regulatory approval.

https://www.opko.com/what-we-do/our-technology

[XenaLives]

So BlackRock and Vanguard own 5% each, 32% total institutions:

 
 File Date	Form	Security		Prev 
 Shares	Current     Shares	Change(Percent) 
 Ownership   (Percent)   Change  (Percent) 
  
  
 2022-02-10	13G/A	VANGUARD GROUP INC		34,450,154	35,725,424	3.70	5.24	1.95 
 2022-02-01	13G/A	BlackRock Inc.		        37,716,833	34,390,912	-8.82	5.00	-10.71

https://fintel.io/so/us/opk

[XenaLives]

I was looking for a company that was working on this...

Thanks for posting it...

https://mma.prnewswire.com/media/1631016/GeneDx_logo.jpg

[tredenwater2]

Sorry, its been a while since Ive heard it mentioned and got my pipeline drugs mixed up. It is Oxyntomodulin and not somotrogen. Yes, he was very excited and I believe its in or has passed a ph2b trial. Anyway he has time to still swallow up chunks of stock “investing right next to shareholders”. Im beginning to think his “shareholders” reference may of been recerring to his “new” friends or his investment “group” buddies. Open market retailshareholders have been bent over time and time again. Its embarrasing, no shame whatsoever coming from management, its almost like he is on auto pilot.. “must buy c o n trolling i n te re st in OPko!”

Lol let me know when you want out and I will sell another block, it’s guaranteed to go up as soon as I do.

[game7alcs]

I remember how excited he got a few years ago in a CC talking about OPKO88003 the drug for diabetes and weight loss. Fast forward to now and nothing really has happened with it. Leader Ed seems to have been put together just for this JV. Somatrogon will be approved in US but Pfizer doesn’t seem to anxious to get that going where it has been approved. lol looonnngggggg is an understatement.

[tredenwater2]

Perhaps at 51% ownership/control between his “group” and Jane Hasaio and her “group” the “financials” will start to jump off the page a bit more. Suuuuucchhhh a loooonngggg slooooowwwwss processssssssss! End game….control before Somotrogen (sp?), the diet drug, imo! Forget all the rest of the pipeline, he really likes the diet drug and its market.

[game7alcs]

750,000 shares bought by Dr Frost. I have no answer for that.

[game7alcs]

Tred, I couldn’t agree more. For the longest time I was fooled to believe that following a successful billionaire made sense. Now I know differently. I will start decreasing my investment here. I have to hold a core position because of my price average. Big long lesson learned here. If it wasn’t for Dr Cohen we would be in the $1s

[tredenwater2]

I feel your pain game! This company is like a reverse mortgage on your moms home. Every month/year “Bank” Frost gobbles up shares of a company that cant string together 2-3 quarters of positive earnings! I believe his goal of majority ownership is aligned with financials released. In other words why drive the price up on great news when all it does is hurt your ultimate agenda. Just string together another loss QoQ, financial genius, not! How many companies Board of Directors has Frost been on led? Truly comical!

The closer things get to approval, the worse the balance sheet and stock price looks. It the opposite of what investors would expect.

[jgstockhunter]

These guys are deliberately reporting bad results. Cash on hand went from 72 million to 134 million dollars. balance sheet had 0 inventory last year quarter but this year we have 315 million dollars of inventory and we cash expensed cost of building inventory.
What happened to accrual accounting? And they mumble through the conference call without explaining anything about revenue dropped 100 million while administrative expenses went up 38 million. 494 mil revs last year 49 mil profit this year qtr 63 mil loss on 400 mil in revs

[game7alcs]

What a horrible cc. I think everybody has lost interest. There were like 4 questions.

[game7alcs]

FU Rubin you POS

[game7alcs]

Listening in on this call and just want to scream. Listening to Dr Frost makes me sick. I have reached my end with these EMPTY promises and dreams. Only these idiots could have $1.8 bln in revs and still lose money with nothing to speak of in the pipeline.

[game7alcs]

It looks like they brought their F game. Bunch of friggin morons. $400+ mill in revs and they lose $68 mil? What do they spend the money on? Somebody explain this to me.

[game7alcs]

He must have been taught by the same people as Adam Logal and Steve Rubin

[game7alcs]

No news at all leading up to earnings. They better come with their A game or personally I will start a process of selling. They have had more than ample time.

[game7alcs]

That’s an understatement

[OPKOHEALTH2022]

Screw Joe Biden is the worse president in history he deserves to be impeach .

[game7alcs]

Management with the exception of Dr Cohen are a disgrace. Can’t imagine hat they would do without a billion dollar backer.

[OPKOHEALTH2022]

Rayaldee has been a failure or should I say management has been a failure ?

[OPKOHEALTH2022]

Frosty buying shares lately here ? this stock has been a disaster for longs .

[game7alcs]

OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

[nbm16yankees]

Pfizer, OPKO Get EU OK for NGENLA Injection for Pediatric Growth-Hormone Deficiency
11:25 am ET February 15, 2022 (Dow Jones)

Pfizer Inc. and OPKO Health Inc. on Tuesday said the European Commission has approved NGENLA, their once-weekly injection for children ages three and older with growth-hormone deficiency.

The companies said the approval of the drug, also known as somatrogon, reduces the frequency of required injections from once daily.

New York drug maker and OPKO, a Miami healthcare-services company, signed a worldwide agreement in 2014 to develop and commercialize somatrogon for growth-hormone deficiency.

The U.S. Food and Drug Administration last month turned away the application seeking approval of somatrogon. Pfizer at the time said it would evaluate the FDA's comments and work with the agency to determine the path forward.



Write to Colin Kellaher at [e-mail]



(END) Dow Jones Newswires

February 15, 2022 11:25 ET (16:25 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

[game7alcs]

Guess Dr Frost bought another 100k? Nothing going on then. Just surprising no earnings call announcement yet.

[game7alcs]

Last years 4th qtr full year call was announced on Feb 3rd for a Feb 18th cc.. probably nothing but just mentionable.

[game7alcs]

I would have expected an earnings call announcement this week for next week.. maybe it’s going to be later than expected

[game7alcs]

Pfizer sells vaccine. OPKO has Rayaldee. What does anybody think will happen there?

[game7alcs]

This link only shows a 2026 estimate of $113 mil in sales?

https://www.evaluate.com/vantage/articles/insights/nme-approvals-snippets/us-fda-approval-tracker-january

[game7alcs]

Nice post.. need to red through again to respond.

[game7alcs]

Dr Frost buys 150k more shares

[tredenwater2]

So, owns roughly 28% and his other trust owns a small chunk. Jane owns a few 0’s with her clan too…..whats the end game? The man doesnt need money otherwise we would all be getting rich. Sitting around growing old waiting for a $15 a share buyout from Pfizer seems kind of a weak ending? Still no insiders selling and

On another note I wonder how those Russian ties are looking about now with the pharma partnership, what was the name Pharmaset or something close? I get mesmerized trying to remember back through the dozens and dozens of partnerships, shell start ups, reverse mergers, bankruptcies, name changes, etc that have taken place over the last decade but through it all here we sit in the high 2’s with
Frost still “investing alongside shareholders” gobbling up shares like pez candy waiting to “make new friends with short sellers” (paraphrased)…… or rekindle old ones?

While markets are tricky, Opko still seems to be the “trickiest” of all to invest in!

“And the trickiest investment award goes to Opko Health for the 10th year in a row setting an all time high new record!”